AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21455088 — intervention group
Group type: COMPARATOR
Intervention: Saline pretreatment/saline admixture
Number of subjects: 151
Study 19803233 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy at Shenque (CV 8)
Number of subjects: 246
Study 19803233 — intervention group
Group type: COMPARATOR
Intervention: Routine ward treatment of stroke (control group)
Number of subjects: 246
Study 19803233 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy
Number of subjects: 246
Study 17155937 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg orally 1 hour before surgery (group E)
Number of subjects: 30
Study 17155937 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet orally 1 hour before surgery (group C)
Number of subjects: 30
Study 15103536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment programme (18 sessions)
Number of subjects: 20
Study 15103536 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (WL)
Number of subjects: 20
Study 10872648 — intervention group
Group type: EXPERIMENTAL
Intervention: Teverelix 5 mg
Number of subjects: 6
Study 10872648 — intervention group
Group type: EXPERIMENTAL
Intervention: Teverelix 3 mg
Number of subjects: 6
Study 10872648 — intervention group
Group type: EXPERIMENTAL
Intervention: Teverelix 0.5 mg
Number of subjects: 6
Study 10872648 — intervention group
Group type: EXPERIMENTAL
Intervention: Teverelix
Number of subjects: 6
Study 10872648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9361543 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice teaching for 5 weeks
Number of subjects: 225
Study 9361543 — intervention group
Group type: COMPARATOR
Intervention: Hospital teaching for 5 weeks
Number of subjects: 225
Study 8237139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (20-60 mg daily)
Number of subjects: 26
Study 8237139 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive)
Number of subjects: 26
Study 3925112 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethyl penicillin (250 mg qid) for 10 days
Number of subjects: 16
Study 3925112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30866666 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 239
Study 30866666 — intervention group
Group type: COMPARATOR
Intervention: RVEF
Number of subjects: 239
Study 28521549 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost 0.1% lotion
Number of subjects: 100
Study 28521549 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil 5% lotion
Number of subjects: 100
Study 28521549 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.1% solution
Number of subjects: 100
Study 28521549 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of latanoprost lotion and betamethasone valerate solution
Number of subjects: 100
Study 28521549 — intervention group
Group type: COMPARATOR
Intervention: Vehicle lotion (control group)
Number of subjects: 100
Study 27010596 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (weekly for 5 consecutive weeks)
Number of subjects: 48
Study 27010596 — intervention group
Group type: COMPARATOR
Intervention: Usual care (physical therapy, analgesia, and/or antiinflammatory drugs)
Number of subjects: 48
Study 24559000 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous enteral nutrition (ENT during 24 hours continuously)
Number of subjects: 41
Study 24559000 — intervention group
Group type: COMPARATOR
Intervention: Intermittent enteral nutrition (ENT during 18 hours with a 6‐hour nocturnal pause)
Number of subjects: 41
Study 24559000 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous enteral nutrition
Number of subjects: 41
Study 24559000 — intervention group
Group type: COMPARATOR
Intervention: Intermittent enteral nutrition
Number of subjects: 41
Study 22118560 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin, 5000 IU weight-adjusted dosage) with aspirin 80 mg
Number of subjects: 139
Study 22118560 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 80 mg alone
Number of subjects: 139
Study 22118560 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin with aspirin
Number of subjects: 139
Study 20651016 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 202
Study 20651016 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 202
Study 17233681 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity PRMST plus placebo
Number of subjects: 29
Study 17233681 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity PRMST plus MA
Number of subjects: 29
Study 17233681 — intervention group
Group type: COMPARATOR
Intervention: Low-resistance exercises plus placebo
Number of subjects: 29
Study 17233681 — intervention group
Group type: COMPARATOR
Intervention: Low-resistance exercises plus MA
Number of subjects: 29
Study 17233681 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity PRMST
Number of subjects: 29
Study 15836565 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A (BOTOX)
Number of subjects: 355
Study 15836565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 11964931 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced particle filtration
Number of subjects: 396
Study 11964931 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature decrease
Number of subjects: 396
Study 9788076 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional wavelet analysis
Number of subjects: 0
Study 9788076 — intervention group
Group type: COMPARATOR
Intervention: Established methods
Number of subjects: 0
Study 7589040 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 8
Study 7589040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2488034 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical deoxycytidine 10(‐4) M
Number of subjects: 13
Study 2488034 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% prednisolone phosphate
Number of subjects: 13
Study 2488034 — intervention group
Group type: COMPARATOR
Intervention: Benzalkonium chloride (BAC) (0.004‐0.02%)
Number of subjects: 13
Study 2488034 — intervention group
Group type: COMPARATOR
Intervention: Thimerosal (TMS) (0.001‐0.004%)
Number of subjects: 13
Study 2488034 — intervention group
Group type: COMPARATOR
Intervention: Chlorobutanol (CHB) (0.2‐0.5%)
Number of subjects: 13
Study 2488034 — intervention group
Group type: COMPARATOR
Intervention: Trifluridine (TFT) (1.0%)
Number of subjects: 13
Study 2488034 — intervention group
Group type: COMPARATOR
Intervention: Ethyldeoxuridine (EDU) (2.0%)
Number of subjects: 13
Study 2488034 — intervention group
Group type: COMPARATOR
Intervention: Idoxuridine (IDU) (0.1%)
Number of subjects: 13
Study 2488034 — intervention group
Group type: COMPARATOR
Intervention: (E)‐5(2‐bromovinyl)‐2'‐deoxyuridine (BVDU) (0.1%)
Number of subjects: 13
Study 2488034 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 13
Study 2488034 — intervention group
Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 13
Study 2488034 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 13
Study 2488034 — intervention group
Group type: COMPARATOR
Intervention: Neomycin
Number of subjects: 13
Study 334230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (50-225 mg daily for 2-26 weeks)
Number of subjects: 0
Study 334230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 0
Study 334230 — intervention group
Group type: COMPARATOR
Intervention: Placebo, imipramine, desipramine, viloxazine, nortriptyline, combination of amitriptyline and chlordiazepoxide, diazepam
Number of subjects: 0
Study 30827001 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC followed by gastrectomy + adjuvant chemotherapy (Arm B)
Number of subjects: 300
Study 30827001 — intervention group
Group type: COMPARATOR
Intervention: Gastrectomy + adjuvant chemotherapy with S‐1 (Arm A)
Number of subjects: 300
Study 28294380 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 64
Study 28294380 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 64
Study 28294380 — intervention group
Group type: COMPARATOR
Intervention: Intra-oral placebo appliance
Number of subjects: 64
Study 26357697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge Preservation (RP)
Number of subjects: 48
Study 26357697 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Healing (EXT)
Number of subjects: 48
Study 26357697 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 22875662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage pessary
Number of subjects: 203
Study 22875662 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (Control)
Number of subjects: 203
Study 21200004 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK
Number of subjects: 217
Study 21200004 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 217
Study 19338147 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoliu Baofei Pill (XBP) plus chemotherapy
Number of subjects: 40
Study 19338147 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 40
Study 17876179 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback-assisted relaxation (6 sessions over 4 weeks)
Number of subjects: 24
Study 17876179 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 24
Study 15664791 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose testosterone replacement therapy
Number of subjects: 34
Study 15664791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11202817 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretically administered lidocaine (anesthetic)
Number of subjects: 0
Study 11202817 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 11202817 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study 9276197 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy (11 patients)
Number of subjects: 46
Study 9276197 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with bromocriptine and levodopa (35 patients)
Number of subjects: 46
Study 8351163 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (0.5 mg) + Sublingual nifedipine (10 mg)
Number of subjects: 36
Study 8351163 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (0.5 mg)
Number of subjects: 36
Study 8351163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3032470 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV1 (cyclophosphamide 600 mg m‐2 i.v., adriamycin 50 mg m‐2 i.v., etoposide 500 mg m‐2 p.o. on day 3)
Number of subjects: 54
Study 3032470 — intervention group
Group type: COMPARATOR
Intervention: CAV5 (cyclophosphamide and adriamycin as for CAV1, etoposide 500 mg m‐2 given in divided dose over days 3‐7)
Number of subjects: 54
Study 29389142 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive condition participants received incentives for attending pre‐ and postbirth treatment contacts: $25 for each of 6 prebirth provider visits, $25-40 for each of 4 postbirth home visits, $20 for each of 5 postbirth counseling calls, and $40 for biochemically verified abstinence at Week 1 and 6-month visits.
Number of subjects: 1014
Study 29389142 — intervention group
Group type: COMPARATOR
Intervention: Control condition participants received only $40 for attendance at the Week 1 and 6-month postbirth visits.
Number of subjects: 1014
Study 28809814 — intervention group
Group type: EXPERIMENTAL
Intervention: Yerba Maté (YM)
Number of subjects: 12
Study 28809814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 12
Study 26576755 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-down positioning
Number of subjects: 192
Study 26576755 — intervention group
Group type: COMPARATOR
Intervention: Face-forward positioning
Number of subjects: 192
Study 24500556 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet blood glucose monitoring system (IBGMS)
Number of subjects: 57
Study 24500556 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 57
Study 24500556 — intervention group
Group type: COMPARATOR
Intervention: IBGMS and RT-CGM
Number of subjects: 57
Study 21665048 — intervention group
Group type: EXPERIMENTAL
Intervention: New micronized powder formulation of artemisinin (160 or 500 mg)
Number of subjects: 15
Study 21665048 — intervention group
Group type: COMPARATOR
Intervention: Previous standard Vietnamese formulation of artemisinin
Number of subjects: 15
Study 18280375 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel applied during the first postoperative week
Number of subjects: 73
Study 18280375 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine rinse used during the first postoperative week
Number of subjects: 73
Study 17065884 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation strategy (tidal volume of 9 ml/kg during two-lung ventilation, reduced to 5 ml/kg during one-lung ventilation; positive end-expiratory pressure 5 cm H2O throughout the operative time)
Number of subjects: 52
Study 17065884 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation strategy
Number of subjects: 52
Study 17065884 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation strategy (tidal volume of 9 ml/kg during two-lung and one-lung ventilation; no positive end-expiratory pressure)
Number of subjects: 52
Study 12942334 — intervention group
Group type: EXPERIMENTAL
Intervention: Information letter focused on workplace (n=1,468)
Number of subjects: 2164
Study 12942334 — intervention group
Group type: COMPARATOR
Intervention: Information letter focused on home (n=696)
Number of subjects: 2164
Study 10357295 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V potassium, 250 mg 3 times daily (n = 239)
Number of subjects: 478
Study 10357295 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V potassium, 500 mg 2 times daily (n = 239)
Number of subjects: 478
Study 8687515 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times daily)
Number of subjects: 24
Study 8687515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1920391 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release carbamazepine (SR) preparation divided into two daily doses
Number of subjects: 20
Study 1920391 — intervention group
Group type: COMPARATOR
Intervention: Conventional carbamazepine (C) preparation divided into three daily doses
Number of subjects: 20
Study 7038182 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% trolamine salicylate cream
Number of subjects: 25
Study 7038182 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 25
Study 30482545 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to physical activity guidelines as per REGICOR questionnaire
Number of subjects: 243
Study 30482545 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical activity reported in RAPA 1 questionnaire
Number of subjects: 243
Study 30482545 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance on chair test (> 15 vs ≤ 15 repetitions)
Number of subjects: 243
Study 31047804 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (5·4 mg/kg or 6·4 mg/kg administered intravenously once every 3 weeks)
Number of subjects: 44
Study 31047804 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 44
Study 29052025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose (ULD) technique for CTCA
Number of subjects: 82
Study 29052025 — intervention group
Group type: COMPARATOR
Intervention: Routine CTCA (control group)
Number of subjects: 82
Study 25761136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice condition
Number of subjects: 20
Study 25761136 — intervention group
Group type: COMPARATOR
Intervention: No ice condition
Number of subjects: 20
Study 25761136 — intervention group
Group type: EXPERIMENTAL
Intervention: Target force at 50% of MVIC
Number of subjects: 20
Study 25761136 — intervention group
Group type: EXPERIMENTAL
Intervention: Target force at 20% of MVIC
Number of subjects: 20
Study 24382118 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium mesh shaped on a 3D printed model of a mirrored intact orbit
Number of subjects: 57
Study 24382118 — intervention group
Group type: COMPARATOR
Intervention: Ultra-high molecular weight polyethylene (UHMWPE) implant manufactured by CAM milling
Number of subjects: 57
Study 21731015 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 0
Study 21731015 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage and debridement of infected necrosis
Number of subjects: 0
Study 21731015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal infection
Number of subjects: 0
Study 21731015 — intervention group
Group type: COMPARATOR
Intervention: Antifungal prophylaxis
Number of subjects: 0
Study 19832962 — intervention group
Group type: EXPERIMENTAL
Intervention: 405 nm wavelength
Number of subjects: 8
Study 19832962 — intervention group
Group type: COMPARATOR
Intervention: 785 nm wavelength
Number of subjects: 8
Study 19832962 — intervention group
Group type: COMPARATOR
Intervention: 830 nm wavelength
Number of subjects: 8
Study 16424586 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-and-shoot IMRT technique
Number of subjects: 10
Study 16424586 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction method for segmental dose errors
Number of subjects: 10
Study 14672636 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent smoking cessation intervention
Number of subjects: 561
Study 14672636 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 561
Study 12198327 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (AIIRA)
Number of subjects: 26
Study 12198327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12198327 — intervention group
Group type: EXPERIMENTAL
Intervention: AIIRA with no >L-NMMA
Number of subjects: 26
Study 12198327 — intervention group
Group type: EXPERIMENTAL
Intervention: >L-NMMA co-infusion
Number of subjects: 26
Study 9790362 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 52
Study 9790362 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 52
Study 7487259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 237
Study 7487259 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 237
Study 2270560 — intervention group
Group type: EXPERIMENTAL
Intervention: Single gutta-percha point with sealer (chloropercha)
Number of subjects: 92
Study 2270560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral condensation of gutta-percha
Number of subjects: 92
Study 338643 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microgram moxestrol (R 2858)
Number of subjects: 6
Study 338643 — intervention group
Group type: COMPARATOR
Intervention: 25 microgram ethinyl estradiol
Number of subjects: 6
Study 6623278 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey milk product (60% liquid whey milk, 40% whole cow's milk, 0.5% skimmed milk powder)
Number of subjects: 30
Study 6623278 — intervention group
Group type: COMPARATOR
Intervention: Whole cow's milk (control)
Number of subjects: 30
Study 30890382 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week 4-site ID regimen with purified Vero cell rabies vaccine (PVRV; Verorab®) without rabies immunoglobulin (RIG) (G1)
Number of subjects: 600
Study 30890382 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week 4-site ID regimen with PVRV and purified equine rabies immunoglobulin (pERIG) (G2)
Number of subjects: 600
Study 30890382 — intervention group
Group type: COMPARATOR
Intervention: TRC 28-day 2-site ID regimen with PVRV and pERIG (G3)
Number of subjects: 600
Study 30347561 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication of 1 day prior to surgery (30 eyes)
Number of subjects: 60
Study 30347561 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication of 3 days prior to surgery (30 eyes)
Number of subjects: 60
Study 30347561 — intervention group
Group type: COMPARATOR
Intervention: Comparison of dry eye classification between both groups
Number of subjects: 60
Study 27501409 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype device for drug administration (scanning required before injection)
Number of subjects: 10
Study 27501409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prototype device)
Number of subjects: 10
Study 24606876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group viewed a slideshow focused on healthy snack food affordability
Number of subjects: 66
Study 24606876 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 66
Study 22689690 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated IFNα2a weekly for 48 weeks
Number of subjects: 1233
Study 22689690 — intervention group
Group type: EXPERIMENTAL
Intervention: albumin‐IFNα2b every 2 weeks for 48 weeks
Number of subjects: 1233
Study 19910118 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (including Omnibus cognitive-behavioral therapy, relaxation therapy, and biofeedback)
Number of subjects: 1247
Study 19910118 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered interventions
Number of subjects: 1247
Study 19910118 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapies
Number of subjects: 1247
Study 19910118 — intervention group
Group type: COMPARATOR
Intervention: Psychological intervention
Number of subjects: 1247
Study 18070255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification programme
Number of subjects: 55
Study 18070255 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55
Study 16287389 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative behavioral couple therapy
Number of subjects: 134